X
LGND icon

Xponance’s Ligand Pharmaceuticals LGND Stock Holding History

Xponance’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
1,839
+303
+20% +$59.9K ﹤0.01% 1165
2025
Q4 		$290K Buy
1,536
+37
+2% +$7.11K ﹤0.01% 1202
2025
Q3 		$266K Buy
+1,499
New +$223K ﹤0.01% 1227
2021
Q3 		– Sell
-4,091
Closed -$335K – 1209
2021
Q2 		$335K Buy
4,091
+1,166
+40% +$97K 0.01% 1045
2021
Q1 		$278K Sell
2,925
-453
-13% -$42.8K 0.01% 977
2020
Q4 		$210K Sell
3,378
-49
-1% -$2.79K ﹤0.01% 1029
2020
Q3 		$204K Buy
3,427
+54
+2% +$3.69K 0.01% 977
2020
Q2 		$235K Buy
+3,373
New +$214K 0.01% 911

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Xponance's LGND Position: Q1 2026 in Review

Xponance increased its Ligand Pharmaceuticals (LGND) stake by 20% in Q1 2026, buying an estimated $59.9K and bringing the position to 1,839 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Xponance first reported a position in LGND in Q2 2020 and has held it in 8 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Xponance held 1,839 shares of Ligand Pharmaceuticals worth $367K as of Q1 2026.
  • Xponance bought 303 Ligand Pharmaceuticals shares in Q1 2026, an estimated $59.9K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1165 holding.
  • Xponance first reported a position in Ligand Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.